neurodegenerative disease

Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders

mycolabadmin

Mushrooms contain special compounds that may help protect our brains as we age. These fungal compounds fight inflammation, reduce harmful free radicals, and help clear out damaged cellular parts—all things that slow down brain aging and diseases like Alzheimer’s and Parkinson’s. While the research looks very promising in lab and animal studies, scientists still need to figure out how to make these compounds work better in the human body and prove they’re safe and effective in patients.

Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells

mycolabadmin

This study examined how two medicinal mushrooms, lion’s mane and Reishi, affect nerve cells in the brain. The researchers found that metabolites from these mushrooms don’t harm brain cells and actually boost protective proteins that support cell health and survival. The mushrooms appear to work through a cellular receptor called AhR, which helps facilitate communication between the gut and the brain. These findings suggest that these mushrooms may help support brain function and protect against neurological problems.

Unveiling the Therapeutic Potentials of Mushroom Bioactive Compounds in Alzheimer’s Disease

mycolabadmin

Mushrooms contain special compounds that may help protect the brain from Alzheimer’s disease. Research shows that eating mushrooms regularly could reduce the risk of memory problems and cognitive decline in older adults. These compounds work by reducing brain inflammation, protecting nerve cells, and helping the brain clear out harmful proteins. While these findings are promising, more human studies are needed to confirm how effective mushrooms are as an Alzheimer’s treatment.

Ergothioneine: An Antioxidative, Neuroprotective and Anti-Inflammatory Compound from Mushroom Residuals

mycolabadmin

Ergothioneine is a powerful antioxidant found mainly in mushrooms that protects brain health and reduces inflammation. Mushroom processing creates large amounts of waste like stems and leftover substrate that actually contain high levels of this beneficial compound. Scientists have developed sustainable methods to extract ergothioneine from this waste, creating opportunities for new health supplements and functional foods while reducing waste and supporting environmental sustainability.

N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer’s disease

mycolabadmin

This research reveals how an abnormal RNA molecule called circRIMS2 contributes to Alzheimer’s disease by damaging brain synapses and impairing memory. Scientists found that circRIMS2 levels are elevated through a chemical modification called m6A methylation, and this causes a cascade of events leading to the destruction of important proteins needed for brain communication. The study shows that blocking this damaging pathway using a specially designed peptide can restore memory and synaptic function in Alzheimer’s disease models, offering hope for new therapeutic approaches.

Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease–A computational study

mycolabadmin

Researchers used computer modeling to test five compounds from Reishi mushrooms against a protein called LRRK2 that is linked to Parkinson’s disease. Ganoderic Acid A showed the strongest binding to this target protein and could potentially be developed into a treatment. The findings suggest that Reishi mushroom compounds may help protect brain cells from the degeneration seen in Parkinson’s disease and warrant further laboratory and animal testing.

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer’s disease through molecular dynamics simulation and MMGBSA

mycolabadmin

Researchers used computer simulations to test five compounds from Reishi mushrooms against Alzheimer’s disease. They found that two compounds, ganoderic acid A and ganoderenic acid B, showed strong potential for blocking a harmful protein involved in the disease. These findings suggest Reishi mushrooms could be a source for new Alzheimer’s treatments, though further laboratory testing is needed.

Research Keyword: neurodegenerative disease

Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders

Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells

Unveiling the Therapeutic Potentials of Mushroom Bioactive Compounds in Alzheimer’s Disease

Ergothioneine: An Antioxidative, Neuroprotective and Anti-Inflammatory Compound from Mushroom Residuals

N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer’s disease

Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease–A computational study

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer’s disease through molecular dynamics simulation and MMGBSA